All In Biotech

Drug Trial Radar · NCT02571712

Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension

Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension

Last checked: Nov 19, 2026Latest source record: Jul 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

750

Actual

Start

Nov 10, 2015

Primary completion

Jun 21, 2018

Study completion Jun 21, 2018

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Oct 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the long-term safety of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) in Chinese patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blocker or prostaglandin analogues.

Conditions

  • Glaucoma, Open-Angle
  • Ocular Hypertension

Interventions

  • bimatoprost 0.03% plus timolol 0.5%Drug

    1 drop of bimatoprost 0.03% plus timolol 0.5% (GANFORT®) instilled in the affected eye once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse EventsTime frame: 24 Weeks

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China

  • Xuanwu Hospital Capital Medical University

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Beijing Tongren hospital Capital Medical University

    Beijing, Beijing Municipality, China

  • Zhongshan Ophthalmic Center, Sun Yat-Sen University

    Guangzhou, Guangdong, China

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology

    Wuhan, Hubei, China

  • Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Eye & ENT Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Eye Hospital

    Tianjin, Tianjin Municipality, China

  • Tianjin Medical University Eye Hospital

    Tianjin, Tianjin Municipality, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Eye Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

  • Henan Provincial Eye Hospital

    Henan, Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.